KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Vertex Pharmaceuticals (VRTX) Change in Cash (2016 - 2025)

Vertex Pharmaceuticals (VRTX) has 17 years of Change in Cash data on record, last reported at $140.0 million in Q4 2025.

  • For Q4 2025, Change in Cash rose 120.71% year-over-year to $140.0 million; the TTM value through Dec 2025 reached $515.6 million, up 108.89%, while the annual FY2025 figure was $515.6 million, 108.89% up from the prior year.
  • Change in Cash reached $140.0 million in Q4 2025 per VRTX's latest filing, up from -$34.2 million in the prior quarter.
  • Across five years, Change in Cash topped out at $1.3 billion in Q4 2022 and bottomed at -$4.6 billion in Q2 2024.
  • Average Change in Cash over 5 years is -$45.1 million, with a median of $252.8 million recorded in 2021.
  • Peak YoY movement for Change in Cash: surged 554.96% in 2022, then crashed 633.74% in 2024.
  • A 5-year view of Change in Cash shows it stood at $519.9 million in 2021, then skyrocketed by 156.78% to $1.3 billion in 2022, then crashed by 155.75% to -$744.3 million in 2023, then increased by 9.19% to -$675.9 million in 2024, then surged by 120.71% to $140.0 million in 2025.
  • Per Business Quant database, its latest 3 readings for Change in Cash were $140.0 million in Q4 2025, -$34.2 million in Q3 2025, and $296.6 million in Q2 2025.